RT @SpillantiniLab: Happy to see that our article about the novel MI2 model of Parkinson's has been viewed 1000s of times and cited several…
RT @SpillantiniLab: Happy to see that our article about the novel MI2 model of Parkinson's has been viewed 1000s of times and cited several…
RT @SpillantiniLab: Happy to see that our article about the novel MI2 model of Parkinson's has been viewed 1000s of times and cited several…
Happy to see that our article about the novel MI2 model of Parkinson's has been viewed 1000s of times and cited several times since it was published ~1 yr ago! @SN_Authors https://t.co/jfqioN5Fwe & @katecholamine will present a poster about it @Parkin
RT @KunathLab: Very interesting findings in this paper from Maria Grazia Spillantini https://t.co/WMMfTKPekG Especially Fig 8 and 9 that sh…
RT @KunathLab: Very interesting findings in this paper from Maria Grazia Spillantini https://t.co/WMMfTKPekG Especially Fig 8 and 9 that sh…
RT @KunathLab: Very interesting findings in this paper from Maria Grazia Spillantini https://t.co/WMMfTKPekG Especially Fig 8 and 9 that sh…
Very interesting findings in this paper from Maria Grazia Spillantini https://t.co/WMMfTKPekG Especially Fig 8 and 9 that show anle138b, a-synuclein modulating drug, rescues striatal dopamine levels and behavioural deficits in #Parkinsons mouse model. http
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
Novel report on the compound anle 138 b in Parkinson's disease model, developed by Armin Giese (#neuropath Munich) and colleagues: https://t.co/zkrRlDj76Z, comment: https://t.co/aKPhREUyb3
RT @ScienceofPD: Researchers from @Cambridge_Uni @McbbTau & colleagues report a new transgenic mouse line (MI2 - human, aggregation-prone t…
Check out the new paper from out lab, which highlights targetting of alpha-synuclein aggregated to treat PD! #spillantinilab!!
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
Fully agree
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @NatRevNeurol: Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new…
RT @NatRevNeurol: Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new…
Researchers from @Cambridge_Uni @McbbTau & colleagues report a new transgenic mouse line (MI2 - human, aggregation-prone truncated 1–120 α-synuclein under TH promoter), & find that treatment with anle138b, from 9 to 12 months of age hasa beneficial
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @ZivGanOr: So now anle138b can treat PD (in mice). It was also shown in the past to treat AD, FTD, MSA, prion disease, all in mice. A ma…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @ZivGanOr: So now anle138b can treat PD (in mice). It was also shown in the past to treat AD, FTD, MSA, prion disease, all in mice. A ma…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model https://t.co/M8A3OPjEBO
RT @ZivGanOr: So now anle138b can treat PD (in mice). It was also shown in the past to treat AD, FTD, MSA, prion disease, all in mice. A ma…
How long are we going to keep doing the same thing and expecting a different result?
So now anle138b can treat PD (in mice). It was also shown in the past to treat AD, FTD, MSA, prion disease, all in mice. A magic drug? Another future failure in humans? I don't know, but I know what happened with previous similar examples. https://t.co/8k0
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
RT @SpillantiniLab: Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising…
Our paper characterising a new model of #Parkinsonsdisease and highlighting #alphasynuclein aggregation as a promising therapeutic target for PD @ParkinsonsUK @ARUKnews @SpringerNature @CamNeuro https://t.co/TBkPAHT0h2